Other Events ·
Veradermics, Inc. announced positive topline results from its Phase 2 'Study 207' clinical trial evaluating VDPHL01…
MANEVeradermics, Inc
Veradermics, Inc. announced positive topline results from its Phase 2 'Study 207' clinical trial evaluating VDPHL01, an extended-release oral minoxidil formulation, for females with mild-to-moderate pattern hair loss. In the 6-month assessment, female participants receiving 4.5 mg doses once or twice daily showed an average non-vellus hair count increase of 22.7 hairs/cm² and 23.3 hairs/cm², respectively. Additionally, 88.9% of the once-daily arm and 90.0% of the twice-daily arm reported improved or much improved hair coverage on the Androgenetic Alopecia Impact Rating Scale. The treatment was generally well tolerated with no treatment-related serious adverse events or cardiac-related adverse events of special interest. Veradermics is a biotechnology company developing hair loss treatments.